Table 1.
Patient characteristics in the overall population
| Characteristics | Overall population | MSS/pMMR population (n = 8702) |
MSI-H/dMMR population (n = 597) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| HRD | HRP | P | q a | HRD | HRP | P | q a | ||
| Total, No. (%) | 9321 | 827 (9.5) | 7875 (90.5) | 438 (73.4) | 159 (26.6) | ||||
| Median age (range), y | 60 (14-90) | 60 (20-90) | 60 (14-90) | .28b | 0.32b | 67 (16-90) | 65 (24-90) | .27b | 0.32b |
| Sex, No. (%) | |||||||||
| Male | 5011 (53.8) | 431 (52.1) | 4299 (54.6) | .17c | 0.25c | 194 (44.3) | 79 (49.7) | .24c | 0.32c |
| Female | 4310 (46.2) | 396 (47.9) | 3576 (45.4) | 244 (55.7) | 80 (50.3) | ||||
| Primary tumor location, No. | 6752 | 602 | 5678 | 346 | 113 | ||||
| Left and rectum, No. (%) | 4455 (66.0) | 394 (65.4) | 3932 (69.2) | .06c | 0.09c | 84 (24.3) | 36 (31.9) | .11c | 0.16c |
| Right, No. (%) | 2297 (34.0) | 208 (34.6) | 1746 (30.8) | 262 (75.7) | 77 (68.1) | ||||
| NA, No. | 2569 | 225 | 2197 | 92 | 46 | ||||
| RAS mutational status, No. | 9316 | 827 | 7870 | 438 | 159 | ||||
| Mut, No. (%) | 4888 (52.5) | 461 (55.7) | 4245 (53.9) | .32c | 0.35c | 122 (27.9) | 48 (30.2) | .58c | 0.58c |
| WT, No. (%) | 4428 (47.5) | 366 (44.3) | 3625 (46.1) | 316 (72.1) | 111 (69.8) | ||||
| NA, No. | 5 | — | 5 | — | — | ||||
| BRAF mutational status, No. | 9312 | 825 | 7870 | 437 | 158 | ||||
| Mut, No. (%) | 846 (9.1) | 66 (8.0) | 532 (6.8) | .18c | 0.25c | 186 (42.6) | 59 (37.3) | .25c | 0.33c |
| WT, No. (%) | 8466 (90.9) | 759 (92.0) | 7338 (93.8) | 251 (57.4) | 99 (62.7) | ||||
| NA, No. | 9 | 2 | 5 | 1 | 1 | ||||
| MS/MMR status, No. | 9299 | — | — | — | — | ||||
| MSI-H/dMMR, No. (%) | 597 (6.4) | — | — | — | — | — | — | — | — |
| MSS/pMMR, No. (%) | 8702 (93.6) | — | — | — | — | ||||
| NA, No. | 22 | — | — | — | — | ||||
| TMB-high (≥10 mut/Mb), No. | 5163 | 479 | 4359 | 249 | 75 | ||||
| Yes, No. (%) | 453 (8.8) | 39 (8.1) | 97 (2.2) | <.001c | <0.001c | 248 (99.6) | 69 (92.0) | <.001c | 0.001c |
| No, No. (%) | 4710 (91.2) | 440 (91.9) | 4262 (97.8) | 1 (0.4) | 6 (8.0) | ||||
| NA, No. | 4158 | 348 | 3516 | 189 | 84 | ||||
| TMB (mut/Mb), No. | 5163 | 479 | 4359 | 249 | 75 | ||||
| Median (range) | 8 (1-513) | 5 (0-446) | 4 (0-115) | <.001b | <0.001b | 37 (4-476) | 27 (5-56) | <.001b | <0.001b |
| PD-L1, No. | 8934 | 786 | 7562 | 416 | 155 | ||||
| Yes, No. (%) | 331 (3.7) | 39 (5.0) | 178 (2.4) | <.001c | <0.001c | 79 (19.0) | 35 (22.6) | .34c | 0.36c |
| No, No. (%) | 8603 (96.3) | 747 (95.0) | 7384 (97.6) | 337 (81.0) | 120 (77.4) | ||||
| NA, No. | 387 | 41 | 313 | 22 | 4 | ||||
| CMS subtypes, No. | 1529 | 135 | 1301 | 77 | 16 | ||||
| CMS1, No. (%) | 201 (13.1) | 17 (12.6) | 122 (9.4) | .28c | 0.34c | 51 (66.2) | 11 (68.7) | .30c | 0.35c |
| CMS2, No. (%) | 449 (29.4) | 33 (24.4) | 415 (31.9) | 0 (0.0) | 1 (6.3) | ||||
| CMS3, No. (%) | 165 (10.8) | 15 (11.1) | 138 (10.6) | 10 (13.0) | 2 (12.5) | ||||
| CMS4, No. (%) | 714 (46.7) | 70 (51.9) | 626 (48.1) | 16 (20.8) | 2 (12.5) | ||||
| NA, No. | 7792 | 692 | 6574 | 361 | 143 | ||||
q is the Benjamini-Hochberg adjusted P value. All statistical tests were 2-sided. CMS = consensus molecular subtype; dMMR = deficient mismatch repair; HRD = homologous recombination deficiency; HRP = homologous recombination proficient; Mb = megabase; MMR = mismatch repair; MS = microsatellite; MSI-H = microsatellite instability high; MSS = microsatellite stable; Mut = mutation; NA = not available; pMMR = proficient mismatch repair; TMB = tumor mutational burden; WT = wild-type; — = unavailable data for subclassification and statistical analysis of clinical characteristics.
P value was calculated using a 2-sided Mann-Whitney test.
P value was calculated using a 2-sided χ2 test.